Navigation Links
For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients
Date:12/8/2010

BURLINGTON, Mass., Dec. 8, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

The Pharmacor 2010 findings from the topic entitled Ovarian Cancer which will publish later this month reveal that, since the publication of data last year from the CALYPSO clinical trial, PLD (Centocor Ortho Biotech/Janssen's Doxil, Merck's Caelyx) is being increasingly used in combination with carboplatin (Bristol-Myers Squibb's Paraplatin, generics) as an alternative to paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin in the second-line, platinum-sensitive population. As a result, Decision Resources forecasts that PLD/carboplatin will replace paclitaxel/carboplatin by 2019 as the gold-standard treatment in this setting in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

According to the findings, urgent unmet need remains for therapies that can delay or prevent progression to platinum-resistant ovarian cancer.

"Experts we interviewed believe that such gains in addressing unmet need will most likely come from novel targeted agents," said Decision Resources Analyst Niamh Murphy, Ph.D. "As such, the need exists to identify other genetic characteristics -- in addition to BRCA1/BRCA2 mutations -- that will lead to the development of novel, molecularly targeted drugs which will benefit patients with ovarian cancer."

The findings also reveal that dramatic growth in the ovarian cancer drug market through 2019 will be driven primarily by the approval and uptake of four premium priced targeted ther
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
(Date:11/21/2014)... Calif. and VIENNA, Va. ... innovative in-home care provider that operates in ... a leading provider of remote caregiving technology. Alta will ... and existing client receiving homecare services. Logo ... this technology is the key to providing the kind ...
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... Confirm Tapentadol Efficacy and Tolerability for Acute Pain PatientsRARITAN, ... to 30 percent of all people who have surgery ... The use of opioid pain medicines during and after ... side effects. Nausea and vomiting are uncomfortable and bothersome ...
... Call to be Held at 9:00 a.m. Eastern Time ... United Therapeutics Corporation (Nasdaq: UTHR ) announced ... (FDA) has approved ADCIRCA(TM) (tadalafil) tablets for oral administration, ... first once-daily phosphodiesterase type 5 (PDE5) inhibitor for the ...
Cached Medicine Technology:New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 3New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 4New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 5New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 6New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 7New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 8FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 2FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 3FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension 4
(Date:11/22/2014)... 22, 2014 Discount-Dress.com is an ... the firm is to increase the company’s online market share ... new selection of bridesmaid dresses and announced a bridesmaid dress ... valid until Dec. 30, 2014. All the dresses from this ... , In fact, Discount-Dress.com is very good at manufacturing ...
(Date:11/22/2014)... Nocturia is defined by the International ... individual has to wake at night one or ... Pipeline Review, H2 2014” provides comprehensive information on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:11/22/2014)... 2014 A petition seeking a ban ... in minimally-invasive hysterectomies and fibroid removal surgeries has ... of October, Bernstein Liebhard LLP reports. According to ... November 21st, 2014. That represents an increase of 456 ... on to the campaign.* , The campaign to ban ...
(Date:11/22/2014)... (HealthDay News) -- The wide variety and complexity of ... for people with food allergies, an expert warns. ... types of food allergies that it can be really ... Guha Krishnaswamy, director of allergy and clinical immunology at ... news release. "If you know you have food ...
(Date:11/22/2014)... New York, New York (PRWEB) November 22, 2014 ... been filed on behalf of patients who allegedly developed ... move forward in the federal multidistrict litigation now underway ... Liebhard LLP reports. According to court documents, the litigation ... at 10:00 a.m. The Court has directed Lead Counsel ...
Breaking Medicine News(10 mins):Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 2Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 3Health News:Power Morcellator Petition Gains More than 450 Signatures Since October, Bernstein Liebhard LLP Reports 4Health News:'Tis the Season of Challenges for Those With Food Allergies 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... Valley Credits Outsourcing Support as Contributor to Profit Gain ... CSC (NYSE: CSC ) today announced ... business process outsourcing (BPO) services for Aspen Valley Hospital ... disclosed.Under the new agreement, CSC will continue to provide ...
... AMERIGROUP Corporation (NYSE: AGP ) announced today ... Nevada began offering healthcare services to individuals enrolled in ... beginning February 1, 2009. "We,re pleased to begin serving ... Carlson, AMERIGROUP Chairman and Chief Executive Officer. "We ...
... in your fridge, chances are you,ll try it, experts say , , ... that expired yogurt at the back of the fridge? What about ... , If you,re like most Americans, you,ll take the chance, a ... people would quickly reject at the supermarket are much more eagerly ...
... Feb. 2 Despite increasingly dire economic news ... where demand for candidates far exceeds supply. Rehabilitation ... professionals among healthcare staffing agencies and medical facilities. ... employment slowdown, that is not the case for ...
... Feb. 2 EDI Health Group, Inc. (EHG), ... for patients, payers and providers in the dental ... (Nasdaq: QSII ) to serve as ... Division (QSI) and its providers and payers. , ...
... from celiac diseaseANN ARBOR, Mich., Feb. 2 Dorothy Carpenter ... a bite of bread or pasta could lead to terrible ... of Michigan Health System physician recognized it as celiac ... mass, a cancer that forced doctors to remove part of ...
Cached Medicine News:Health News:CSC Signs Five-Year Outsourcing Extension With Aspen Valley Hospital 2Health News:AMERIGROUP Health Plan in Nevada Begins Serving Medicaid Enrollees 2Health News:You Own It, You'll Eat It 2Health News:You Own It, You'll Eat It 3Health News:Need for Traveling Therapists Boosts Demand for Lead Services of AlliedTravelCareers.com 2Health News:EDI Health Group Selected by Quality Systems to Facilitate EDI Transactions Between Payers and Large Dental Group Practices 2Health News:EDI Health Group Selected by Quality Systems to Facilitate EDI Transactions Between Payers and Large Dental Group Practices 3Health News:GI Condition Once Thought Rare is Common in U.S. 2Health News:GI Condition Once Thought Rare is Common in U.S. 3
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
Malaria device / strip (3 line, PAN-pLDH, P.f.-HRP2)...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
High sensitive, specific one step immunochromatographic assay for human infectious disease...
Medicine Products: